MEIRAGTX HOLDINGS PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.285 USD | +2.82% |
|
-7.44% | -24.72% |
| May. 15 | Transcript : MeiraGTx Holdings plc Presents at Bank of America Health Care Conference 2024, May-15-2024 10:40 AM | |
| May. 09 | Earnings Flash (MGTX) MEIRAGTX Reports Q1 Revenue $697,000 | MT |
Financials (USD)
| Sales 2024 * | 49.77M | Sales 2025 * | 273M | Capitalization | 340M |
|---|---|---|---|---|---|
| Net income 2024 * | -108M | Net income 2025 * | 116M | EV / Sales 2024 * | 6.83 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.25 x |
| P/E ratio 2024 * |
-3.42
x | P/E ratio 2025 * |
4.63
x | Employees | 402 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 65.01% |
More Fundamentals
* Assessed data
More news
Latest transcript on MeiraGTx Holdings plc
More recommendations
More press releases
| 1 day | +2.82% | ||
| 1 week | -7.44% | ||
| Current month | +8.30% | ||
| 1 month | +8.74% | ||
| 3 months | -8.88% | ||
| 6 months | -2.49% | ||
| Current year | -24.72% |
1 week
5.03
5.93
1 month
4.685.93
Current year
4.687.57
1 year
3.498.35
3 years
3.4924.89
5 years
3.4930.23
10 years
3.4930.23
| Managers | Title | Age | Since |
|---|---|---|---|
Richard Giroux
FOU | Founder | 61 | 15-03-19 |
| Chief Executive Officer | 59 | 15-03-19 | |
Robert Zeldin
CTO | Chief Tech/Sci/R&D Officer | 61 | 20-08-04 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Debra Yu
BRD | Director/Board Member | 59 | 22-04-24 |
Thomas Shenk
BRD | Director/Board Member | 77 | 15-05-31 |
Keith Harris
CHM | Chairman | 71 | 15-05-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.03% | 0 M€ | 0.00% | - | |
| 0.02% | 0 M€ | 0.00% | - | |
| 0.00% | 9 M€ | +10.11% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-24 | 5.285 | +2.82% | 103,081 |
| 24-05-23 | 5.14 | -9.19% | 265,407 |
| 24-05-22 | 5.66 | +2.91% | 633,630 |
| 24-05-21 | 5.5 | -0.72% | 283,577 |
| 24-05-20 | 5.54 | -2.98% | 207,903 |
Delayed Quote Nasdaq, May 24, 2024 at 04:00 pm EDT
More quotes
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage gene therapy company. The Company is focused on three distinct areas of unmet medical need: ocular diseases, including inherited retinal diseases (IRDs), as well as large degenerative ocular diseases, severe forms of xerostomia and neurodegenerative diseases. Its product pipeline includes botaretigene sparoparvovec or bota-vec, for the treatment of X-linked retinitis pigmentosa related to mutations in the retinitis pigmentosa GTPase regulator gene or XLRP-RPGR; AAV-hAQP1 for the treatment of radiation-induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogrenâs Syndrome; AAV-GAD for the treatment of Parkinsonâs Disease; AAV-RPE65 for the treatment of RPE65-asociated retinal dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of achromatopsia; AAV-AIPL1 for the treatment of LCA4, and AAV-RDH12 for the treatment of RDH12 mutation-associated retinal dystrophy.
Calendar
2024-06-06
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
5.285
USD
Average target price
21.2
USD
Spread / Average Target
+301.14%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -24.72% | 340M | |
| +12.30% | 118B | |
| +12.15% | 106B | |
| -8.14% | 23.4B | |
| -1.69% | 21.78B | |
| -10.60% | 18.09B | |
| -41.25% | 16.72B | |
| -15.33% | 15.97B | |
| +5.80% | 14.03B | |
| +28.03% | 11.67B |
- Stock Market
- Equities
- MGTX Stock
